| ||||
| ||||
[Skin & Allergy News 30(10):16, 1999. © 1999 International Medical News Group.]
The addition of tamoxifen to the triple combination of cisplatin, dacarbazine, and carmustine does not boost response or survival in patients with advanced malignant melanoma, said Dr. Edward T. Creagan of the Mayo Clinic in Rochester, Minn., and his associates.
Median response rates were 27% for 92 patients on the four-drug combination and 33% for 92 patients not taking tamoxifen. Median survival was 6.9 months in the first group and 6.8 months in the latter in the first randomized phase III trial to assess the adjunctive therapy (J. Clin. Oncol. 17[6]:1884-90, 1999).
Time to progression was a median of 3.1 months in the tamoxifen group and 3.4 months in the triple-combination group. None of these differences was statistically significant.
|
